Due to a high load of modelling projects, the rate of submission via the website has been reduced.
For a much higher submission rate, please use the Modelling API.

A0A0H3LFJ7 (A0A0H3LFJ7_MYCTE) Mycobacterium tuberculosis (strain ATCC 35801 / TMC 107 / Erdman)

Enoyl-[acyl-carrier-protein] reductase [NADH] UniProtKBInterProInteractive Modelling

269 aa; Sequence (Fasta) ; 12 identical sequences

Available Structures

116 Experimental Structures

DescriptionPDB IDOligo-stateRangeLigands
Crystal structure of InhA:01 TCR in complex with HLA-E (Y84C) bound to InhA (53-61 GCG) Heteromer
P13747; P61769; P9WGR1;
53-64
EDO;
Assess
HLA-E*01:03 in complex with Mtb44 Heteromer
P13747; P61769; P9WGR1;
53-61
SO4;
Assess
HLA-E*01:03 in complex with the Mtb44 peptide variant: Mtb44*P2-Gln. Heteromer
P13747; P61769; P9WGR1;
53-61
SO4;
Assess
Crystal structure of InhA:01 TCR in complex with HLA-E bound to InhA (53-61) Heteromer
P13747; P61769; P9WGR1;
53-61
Assess
HLA-E*01:03 in complex with the Mtb44 peptide variant: Mtb44*P9-Phe. Heteromer
P13747; P61769; P9WGR1;
53-61
SO4;
Assess
Crystal structure of InhA:01 TCR in complex with HLA-E (S147C) bound to InhA (53-61 H3C) Heteromer
P13747; P61769; P9WGR1;
53-61
Assess
HLA-E*01:03 in complex with the Mtb44 peptide variant: Mtb44*P2-Phe. Heteromer
P13747; P61769; P9WGR1;
53-61
ZN;SO4;
Assess
Crystal structure of InhA:01 TCR in complex with HLA-E (F116C) bound to InhA (53-61 H4C) Heteromer
P13747; P61769; P9WGR1;
53-60
EDO;
Assess
structure of InhA from mycobacterium tuberculosis in complex with inhibitor 7-((1-(3-Hydroxy-4-phen…homo-4-mer1-269
NAD;VZR;
Assess
Structure of the enoyl-ACP reductase of Mycobacterium tuberculosis InhA, inhibited with the active …homo-4-mer2-269
NAD;ZID;EPE; 16×DMS;NA;
Assess
InhA in complex with a DNA encoded library hithomo-4-mer2-269
NAD;S72;
Assess
Crystal structure of Mycobacterium tuberculosis InhA in complex with inhibitor PT92homo-4-mer2-269
NAD;2TK;
Assess
structure of InhA from mycobacterium tuberculosis in complex with N-((1-(3-hydroxy-4-phenoxybenzyl)…homo-4-mer2-269
NAD;VZI;EDO;NA;ACT;
Assess
Crystal structure of Mycobacterium tuberculosis enoyl reductase (INHA) complexed WITH 1-CYCLOHEXYL-…homo-4-mer2-269
NAD;641;
Assess
Crystal structure of Mycobacterium tuberculosis enoyl reductase (INHA) complexed with 1-CYCLOHEXYL-…homo-4-mer2-269
NAD;566;
Assess
Mtb InhA complex with Pyradizinone compound 14homo-4-mer2-269
NAD;9G4;MG;
Assess
InhA in complex with a DNA encoded library hithomo-4-mer2-269
NAD;9CV;
Assess
Crystal structure of Mycobacterium tuberculosis enoyl reductase (INHA) complexed with N-(3-bromophe…homo-4-mer2-269
NAD;665;
Assess
Discovery of pyrimidine isoxazoles InhA in complex with compound 23homo-4-mer2-269
NAD;KXU;
Assess
InhA in complex with a DNA encoded library hithomo-4-mer2-269
NAD;EEH;
Assess
Crystal structure of M. tuberculosis InhA in complex with NAD+ and 3-hydroxynaphthalene-2-carboxyli…homo-4-mer2-269
NAD;BZJ;EPE;
Assess
InhA in complex with a DNA encoded library hithomo-4-mer2-269
NAD;MG;9NU;
Assess
InhA in complex with a DNA encoded library hithomo-4-mer2-269
NAD;MG;JDD;
Assess
InhA Y158F mutant in complex with NADH from Mycobacterium tuberculosishomo-4-mer2-269
16×NA;NAD; 24×GOL;MPD;
Assess
crystal structure of M. tuberculosis InhA inhibited by PT70homo-4-mer2-269
NAD;TCU;DMS;
Assess
Discovery of pyrimidine isoxazoles InhA in complex with compound 6homo-4-mer2-269
NAD;MG;HRW;
Assess
Crystal structure of Mycobacterium tuberculosis InhA in complex with inhibitor PT119 in 2.4 M aceta…homo-4-mer2-269
NAD;JUS; 44×ACT;
Assess
CRYSTAL STRUCTURE OF MYCOBACTERIUM TUBERCULOSIS ENOYL REDUCTASE (INHA) COMPLEXED WITH N-(3-CHLORO-2…homo-4-mer2-269
NAD;468;
Assess
Mtb InhA complex with Methyl-thiazole compound 7homo-4-mer2-269
NAD;NA;VMY;
Assess
Discovery of pyrimidine isoxazoles InhA in complex with compound 10homo-4-mer2-269
NAD;UUD;ACT;
Assess
Discovery of pyrimidine isoxazoles InhA in complex with compound 15homo-4-mer2-269
NAD;MG;1PE;A0C;
Assess
How nature bridges the gap: Crystallographic elucidation of pyridomycin binding to InhAhomo-4-mer2-269
NAD;PYW;
Assess
STRUCTURE OF INHA FROM MYCOBACTERIUM TUBERCULOSIS COMPLEXED TO NADHhomo-4-mer2-269
NAD;MPD;DMS;
Assess
Crystal structure of M. tuberculosis InhA inhibited by PT506homo-4-mer2-269
NAD;XTV;
Assess
Crystal structure of InhA bound to triclosan derivativehomo-4-mer2-269
NAD;JPL;
Assess
Crystal structure of InhA bound to triclosan derivative 17homo-4-mer2-269
NAD;8PC;
Assess
Discovery of pyrimidine isoxazoles InhA in complex with compound 9homo-4-mer2-269
NAD;MG;KI5;
Assess
The effect of isoleucine to alanine mutation on InhA enzyme crystallization pattern and inhibition …homo-4-mer2-269
NAD;
Assess
Crystal structure of M. tuberculosis InhA inhibited by PT514homo-4-mer2-269
NAD;53K;CL;
Assess
Crystal structure of M. tuberculosis InhA inhibited by PT512homo-4-mer2-269
NAD;XT0;
Assess
Crystal structure of wild type Enoyl-ACP(CoA) reductase from Mycobacterium tuberculosis in complex …homo-4-mer2-269
ZID;
Assess
Crystal structure of M. tuberculosis InhA inhibited by SKTS1homo-4-mer2-269
NAD;F9T; 20×CL;NA;
Assess
Crystal structure of Isoniazid-resistant I21V Enoyl-ACP(CoA) reductase mutant enzyme from Mycobacte…homo-4-mer2-269
NAI;
Assess
Mtb InhA complex with Methyl-thiazole compound 11homo-4-mer2-269
NAD;IBH;
Assess
crystal structure of M. tuberculosis InhA inhibited by PT70homo-4-mer2-269
NAD;TCU;DMS;
Assess
CRYSTAL STRUCTURE of ISONIAZID-RESISTANT S94A ENOYL-ACP(COA) REDUCTASE MUTANT ENZYME FROM MYCOBACTE…homo-4-mer2-269
Assess
Crystal structure of the InhA:GSK_SB713 complexhomo-4-mer2-269
NAD;713;
Assess
Mycobacterium tuberculosis InhA bound with ETH-NAD adducthomo-4-mer2-269
EAD;
Assess
Crystal Structure of Isoniazid-resistant I21V Enoyl-ACP(COA) Reductase Mutant Enzyme From MYCOBACTE…homo-4-mer2-269
ZID;
Assess
Crystal structure of Isoniazid-resistant I47T Enoyl-ACP(CoA) reductase mutant enzyme from Mycobacte…homo-4-mer2-269
NAI;
Assess
Crystal Structure of Isoniazid-resistant S94A ENOYL-ACP(COA) Reductase Mutant Enzyme from MYCOBACTE…homo-4-mer2-269
ZID;
Assess
Substrate-like binding mode of inhibitor PT155 to the Mycobacterium tuberculosis enoyl-ACP reductas…homo-4-mer2-269
NAD;1S5;CL; 16×2NV;EPE;
Assess
Competition of the small inhibitor PT91 with large fatty acyl substrate of the Mycobacterium tuberc…homo-4-mer2-269
NAD;1US;
Assess
Crystal structure of InhA bound to triclosan derivativehomo-4-mer2-269
NAD;JPM;
Assess
The effect of valine to alanine mutation on InhA enzyme crystallization pattern and substrate bindi…homo-4-mer2-269
NAD;TCU;NA;
Assess
Crystal structure of Mycobacterium tuberculosis enoyl reductase (InhA) inhibited by triclosanhomo-4-mer2-269
TCL;NAD;
Assess
Crystal structure of Isoniazid-resistant S94A Enoyl-ACP(CoA) reductase mutant enzyme from Mycobacte…homo-4-mer2-269
NAI;
Assess
Substrate-binding loop movement with inhibitor PT10 in the tetrameric Mycobacterium tuberculosis en…homo-4-mer2-269
NAD;1TN;
Assess
Encoded library technology as a source of hits for the discovery and lead optimization of a potent …homo-4-mer2-269
KV1;NAD;
Assess
InhA (T2A mutant) complexed with 5-((5-Amino-3-methyl-1H-pyrazol-1-yl)methyl)-N-(1-(2-chloro-6-fluo…homo-4-mer2-269
9WH;NAD;
Assess
Crystal structure of M. tuberculosis InhA inhibited by PT504homo-4-mer2-269
NAD;XTW;
Assess
Crystal structure of M. tuberculosis InhA inhibited by PT511homo-4-mer2-269
NAD;XT3;
Assess
Targeting tuberculosis and malaria through inhibition of enoyl reductase: compound activity and str…homo-4-mer2-269
NAD;TCL;
Assess
Crystal structure of Mycobacterium tuberculosis enoyl reductase (InhA) inhibited by 5-octyl-2-pheno…homo-4-mer2-269
NAD;
Assess
Targeting tuberculosis and malaria through inhibition of enoyl reductase: compound activity and str…homo-4-mer2-269
NAD;GEQ;
Assess
LONG FATTY ACID CHAIN ENOYL-ACP REDUCTASE (INHA) IN COMPLEX WITH AN ISONICOTINIC-ACYL-NADH INHIBITORhomo-4-mer2-269
ZID;
Assess
Mtb InhA complex with Pyradizinone compound 1homo-4-mer2-269
NAD;41I;
Assess
Crystal structure of InhA bound to triclosan derivativehomo-4-mer2-269
NAD;JPJ;
Assess
Crystal structure of M. tuberculosis InhA inhibited by PT501homo-4-mer2-269
NAD;XT5;CL;NA;
Assess
M.TB. ENOYL-ACP REDUCTASE (INHA) IN COMPLEX WITH NAD+ AND C16-FATTY-ACYL-SUBSTRATEhomo-4-mer2-269
NAD;THT;
Assess
Crystal structure of Mycobacterium tuberculosis enoyl reductase (InhA) inhibited by 5-pentyl-2-phen…homo-4-mer2-269
5PP;NAD;
Assess
InhA (T2A mutant) complexed with N-(1-(pyrimidin-2-yl)piperidin-4-yl)acetamidehomo-4-mer2-269
NAD;9W2;
Assess
Structure of the M.tuberculosis enoyl-reductase InhA in complex with GSK625homo-4-mer2-269
NAD;6KA;
Assess
InhA (T2A mutant) complexed with 1-(Pyridin-3-ylmethyl)-3-(1-(pyrimidin-2-yl)piperidin-4-yl)ureahomo-4-mer3-269
NAD;9WE;PO4;
Assess
Crystal structure of M. tuberculosis InhA in complex with NAD+ and 2-pyrazol-1-ylbenzoic acidhomo-4-mer3-269
NAD;LT8;
Assess
Crystal structure of InhA in complex with AP-124 inhibitorhomo-4-mer3-269
JVZ;NAD;
Assess
Crystal structure of M. tuberculosis InhA in complex with NAD+ and 2-(4-chloro-3-nitrobenzoyl)benzo…homo-4-mer3-269
NAD;9FN;
Assess
Crystal structure of M. tuberculosis InhA in complex with NAD+ and 3-(3-chlorophenyl)propanoic acidhomo-4-mer3-269
NAD;LSQ;EPE;
Assess
Structure of the apo form of InhA from Mycobacterium tuberculosishomo-4-mer3-269
MES;
Assess
Crystal structure of M. tuberculosis InhA in complex with NAD+ and 3-[3-(trifluoromethyl)phenyl]pro…homo-4-mer3-269
NAD;LRW;
Assess
Multiple binding modes of inhibitor PT155 to the Mycobacterium tuberculosis enoyl-ACP reductase Inh…homo-4-mer3-269
NAD;1S5;2NV;
Assess
InhA (T2A mutant) complexed with (4-((1H-pyrazol-1-yl)methyl)phenyl)methanolhomo-4-mer3-269
NAD;9VQ; 12×ETX;
Assess
Mycobacterium tuberculosis InhA (S94A) bound with INH-NAD adducthomo-4-mer3-269
ZID;
Assess
Crystal structure of Mycobacterium tuberculosis enoyl reductase complexed with N-(5-chloro-2-methyl…homo-4-mer3-269
NAD;744;
Assess
Mycobacterium tuberculosis InhA-S94A mutant in complex with NADHhomo-4-mer3-269
NAI;
Assess
InhA (T2A mutant) complexed with ethyl 2-methyl-4,5,6,7-tetrahydrobenzo[d]thiazole-6-carboxylatehomo-4-mer3-269
9VZ;NAD; 12×ETX;
Assess
Crystal structure of wild-type of Enoyl-ACP(CoA) reductase from Mycobacterium tuberculosis in compl…homo-4-mer3-269
NAI;LYS;
Assess
InhA (T2A mutant) complexed with 2,6-Dimethyl-3-(1-(pyrimidin-2-yl)piperidin-4-yl)pyridin-4(1H)-onehomo-4-mer3-269
NAD;9W8; 16×ETX;SO4;
Assess
Crystal structure of InhA_T266D:NADH complexhomo-4-mer3-269
NAD;MPD;
Assess
Crystal structure of InhA_T266E:NADH complexhomo-4-mer3-269
NAD;MPD;
Assess
InhA (T2A mutant) complexed with 1-benzyl-3-methyl-1H-pyrazol-5-aminehomo-4-mer3-269
NAD;9W5;
Assess
Crystal structure of InhA(S94A) mutant in complex with OH-141homo-4-mer3-269
NAD;I4I;
Assess
structure of InhA from Mycobacterium tuberculosis in complex with 5-(((4-(2-hydroxyphenoxy)benzyl)(…homo-4-mer3-269
NAD;
Assess
Crystal structure of wild-type InhA:NADH complexhomo-4-mer3-269
NAD;MPD;
Assess
InhA (T2A mutant) complexed with 4-((5-Amino-3-methyl-1H-pyrazol-1-yl)methyl)-N-(2-chloro-4-fluorob…homo-4-mer3-269
9WK;NAD;
Assess
Crystal structure of InhA(S94A) mutant in complex with pyridomycinhomo-4-mer3-269
PYW;
Assess
Crystal structure of M. tuberculosis InhA in complex with NAD+ and N-(3-(aminomethyl)phenyl)-5-chlo…homo-4-mer3-269
NAD;LTK;
Assess
Mycobacterium tuberculosis InhA in complex with NADHhomo-4-mer3-269
NAI;
Assess
The effect of isoleucine to alanine mutation on InhA enzyme crystallization pattern and substrate b…homo-4-mer3-269
NAD;TCU;ETE;EPE;
Assess
Mycobacterium tuberculosis InhA-D148G mutant in complex with NADHhomo-4-mer3-269
NAI;
Assess
Crystal structure of InhA in complex with 3-nitropropanoic acid inhibitorhomo-4-mer3-269
NAD;3NP;GOL;
Assess
Structure of Mycobacterium tuberculosis enoyl-ACP reductase with bound INH-NADP.homo-4-mer3-269
DG1;
Assess
Mycobacterium tuberculosis InhA bound with PTH-NAD adducthomo-4-mer3-269
P1H;
Assess
InhA (T2A mutant) complexed with 2,6-dimethyl-3-phenylpyridin-4(1H)-onehomo-4-mer3-269
9WB;NAD;
Assess
InhA (T2A mutant) complexed with 5-((3,5-dimethyl-1H-pyrazol-1-yl)methyl)-N-ethyl-1,3,4-thiadiazol-…homo-4-mer3-269
9VT;NAD;
Assess
InhA (T2A mutant) complexed with 1-cyclohexyl-3-(pyridin-3-ylmethyl)ureahomo-4-mer3-269
NAD;9VW;ETX;
Assess
Mycobacterium tuberculosis InhA bound to NITD-564homo-4-mer3-269
NAD;3KX;
Assess
Compensation of the effect of isoleucine to alanine mutation by designed inhibition in the InhA enz…homo-4-mer3-269
NAD;53K;
Assess
CRYSTAL STRUCTURE AND FUNCTION OF THE ISONIAZID TARGET OF MYCOBACTERIUM TUBERCULOSIShomo-2-mer2-269
NAD;
Assess
CRYSTAL STRUCTURE AND FUNCTION OF THE ISONIAZID TARGET OF MYCOBACTERIUM TUBERCULOSIShomo-2-mer2-269
NAD;
Assess
Enoyl acyl carrier protein reductase InhA in complex with N-(4-methylbenzoyl)-4-benzylpiperidinemonomer2-269
NAD;4PI;
Assess
CRYSTAL STRUCTURE OF THE INHA FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH AN12855, EBSI 4333.monomer2-269
9JM;
Assess
CRYSTAL STRUCTURE OF THE INHA FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH AN12855, EBSI 4333.monomer2-269
9JA;
Assess
CRYSTAL STRUCTURE OF THE INHA FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH AN12855, EBSI 4333.monomer2-269
9JA;
Assess
Mycobacterium tuberculosis InhA bound to NITD-916monomer2-269
NAD;3KY;
Assess
CRYSTAL STRUCTURE OF THE INHA FROM MYCOBACTERIUM TUBERCULOSIS IN COMPLEX WITH AN12855, EBSI 4333.monomer3-269
9JJ;
Assess

1 SWISS-MODEL model

TemplateOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
6sq5.1.Dhomo-4-mer0.913-269
NAD;LRW;100.00
Assess